Stifel Nicolaus Raises Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $98.00

Mirum Pharmaceuticals (NASDAQ:MIRM) had its price target raised by research analysts at Stifel Nicolaus from $92.00 to $98.00 in a research note issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Stifel Nicolaus’ price objective would suggest a potential upside of 45.72% from the company’s current price.

Several other research analysts have also recently issued reports on MIRM. JMP Securities set a $95.00 target price on shares of Mirum Pharmaceuticals in a report on Wednesday, November 5th. Raymond James Financial reissued a “strong-buy” rating and set a $110.00 price target on shares of Mirum Pharmaceuticals in a research report on Thursday, December 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research report on Wednesday, October 8th. TD Cowen upgraded Mirum Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, September 25th. Finally, Leerink Partners set a $100.00 target price on Mirum Pharmaceuticals in a report on Wednesday, December 10th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Mirum Pharmaceuticals currently has an average rating of “Buy” and an average target price of $96.50.

Mirum Pharmaceuticals Stock Up 4.9%

Shares of NASDAQ MIRM traded up $3.15 on Tuesday, reaching $67.25. 561,595 shares of the company’s stock traded hands, compared to its average volume of 561,326. The business’s 50 day simple moving average is $70.67 and its two-hundred day simple moving average is $63.99. Mirum Pharmaceuticals has a 12 month low of $36.88 and a 12 month high of $78.54. The company has a market cap of $3.46 billion, a price-to-earnings ratio of -78.27 and a beta of 0.42. The company has a quick ratio of 3.16, a current ratio of 3.31 and a debt-to-equity ratio of 1.06.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The company had revenue of $133.01 million during the quarter, compared to analyst estimates of $130.11 million. During the same quarter last year, the company earned ($0.30) EPS. The firm’s revenue for the quarter was up 47.1% on a year-over-year basis. As a group, equities research analysts forecast that Mirum Pharmaceuticals will post -1.43 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. CWM LLC lifted its position in shares of Mirum Pharmaceuticals by 30.8% in the third quarter. CWM LLC now owns 683 shares of the company’s stock worth $50,000 after buying an additional 161 shares in the last quarter. Legal & General Group Plc increased its stake in Mirum Pharmaceuticals by 0.4% in the 2nd quarter. Legal & General Group Plc now owns 43,010 shares of the company’s stock worth $2,189,000 after acquiring an additional 176 shares during the last quarter. MCF Advisors LLC raised its holdings in shares of Mirum Pharmaceuticals by 76.4% during the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after acquiring an additional 185 shares in the last quarter. Teacher Retirement System of Texas boosted its position in shares of Mirum Pharmaceuticals by 2.2% during the 2nd quarter. Teacher Retirement System of Texas now owns 9,903 shares of the company’s stock valued at $504,000 after acquiring an additional 215 shares during the last quarter. Finally, Palumbo Wealth Management LLC boosted its position in shares of Mirum Pharmaceuticals by 4.2% during the 2nd quarter. Palumbo Wealth Management LLC now owns 5,604 shares of the company’s stock valued at $285,000 after acquiring an additional 228 shares during the last quarter.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.